R&D

Commercializing science takes too long, Cook saysRestricted Content

May 25, 2009
Taking science from the laboratory to the commercial market takes too much time and is littered with potential pitfalls along the way.
More

With pharma famine looming, Lilly relying on snack-size dealsRestricted Content

May 4, 2009
J.K. Wall
Compared with some of his pharmaceutical CEO peers these days, John Lechleiter has his company on a diet. Instead of using a mega-merger to bulk up before the famine that patent expirations will bring on the industry next year, Lechleiter has Eli Lilly and Co. burning management fat while looking for smaller companies to munch on.
More

Indiana playing trailblazing role in drive to tailor pharmaceuticals to genetic makeup of individualsRestricted Content

April 13, 2009
Chris O'Malley
Indiana is becoming not only a hotbed of "pharmacogenomics" research, but also a trailblazer in finding practical ways to use it on the practitioner level.
More

Biotech push may help offset generic competition; some analysts skepticalRestricted Content

February 2, 2009
J.K. Wall
Lilly executives want to make biotech their top focus.
More

Lilly taps hedge fund to cut research costs for Alzheimer's drugsRestricted Content

August 11, 2008
J.K. Wall

Eli Lilly and Co.'s unorthodox efforts to develop new treatments for Alzheimer's disease--if successful--could usher in a new approach to drug development. The Indianapolis-based pharmaceutical company announced that a New York hedge fund, TPG-Axon Capital, will invest up to $325 million to help cover the exorbitant development costs of two experimental compounds to treat Alzheimer's disease.

More

Lilly under gun to replace aging blockbuster ZyprexaRestricted Content

November 5, 2007
J.K. Wall
There's a $2 billion hole in Eli Lilly and Co.'s future. That's roughly how much pretax profit Lilly derives each year from its best-seller, Zyprexa, according to calculations by IBJ. And it's how much black ink will start running off Lilly's books once Zyprexa's U.S. and European patents expire in 2011.
More

Lilly still breathing in inhaler pursuitRestricted Content

April 2, 2007
J.K. Wall
Pfizer Inc.'s new inhaled insulin product, Exubera, has stumbled out of the gate. That would appear to keep the door open for Eli Lilly and Co., as well as for other companies racing to develop inhaled insulin. But Pfizer's troubles might cause doctors and patients to sour on all inhaled insulin products.
More

Lilly decides to self-insure for product liabilityRestricted Content

September 4, 2006
Tom Murphy
Eli Lilly and Co. has picked an insurer it knows extremely well to cover future problems in the high-stakes world of product liability litigation--itself. The Indianapolis drugmaker opted for self-insurance after struggling to find coverage in what it terms a "very restrictive insurance market."
More
Page  << 1 2 3 4 5 6 pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT